Novel Biologics to Promote T-Cell-Mediated Depletion of Pathogenic Cell Types in Autoimmune Disease
- Immuno-STAT™ platform enables selective regulation of antigen-specific T-cells
- CUE-501 differentiates from pan-TCEs by selectively engaging existing virus-specific T-cells to deplete pathogenic B cells while minimizing systemic immune activation and CRS risk
- Modular nature of the Immuno-STAT™ platform enables opportunity to target additional pathogenic cell types beyond B cells, opening avenues for precise immunomodulation in autoimmunity